Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?

Clicks: 246
ID: 271443
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In Germany, direct-acting antiviral treatment of former or current drug users with or without opioid substitution therapy can achieve equally high sustained virological response rates as in patients with no history of drug use.
Reference Key
s2018addictiondirect-acting Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Christensen S;Buggisch P;Mauss S;Böker KHW;Schott E;Klinker H;Zimmermann T;Weber B;Reimer J;Serfert Y;Wedemeyer H;;
Journal addiction (abingdon, england)
Year 2018
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/29359361
Keywords
hepatitis c germany National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male aged middle aged odds ratio antiviral agents / therapeutic use* chronic / complications chronic / drug therapy* registries opiate substitution treatment* Opioid-Related Disorders / complications Opioid-Related Disorders / drug therapy* Sustained Virologic Response* pmid:29359361 doi:10.1111/add.14128 stefan christensen peter buggisch heiner wedemeyer lost to follow-up*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.